LivaNova, PLC Announces New Data Reinforce the Clinical Value of the Perceval Sutureless Valve as Safe and Effective Bioprosthesis for Patients in Need of Aortic Valve Replacement
January 27, 2017 at 06:00 pm
Share
LivaNova, PLC announced that a data presentation on the Perceval sutureless valve was unveiled at The Society of Thoracic Surgeons 53rd Annual Meeting (STS), which took place January 21-25, 2017 in Houston. These data highlight the safety, efficiency, and performance of Perceval, the first-ever, truly sutureless surgical valve designed for patients requiring an aortic valve replacement (AVR). The study, Aortic Valve Replacement With Sutureless Perceval Bioprosthesis: Single-Center Experience With 617 Implants, analyzed patients who underwent AVR with the Perceval bioprosthesis. The study found that AVR procedures conducted with Perceval resulted in low mortality and excellent hemodynamic performance for patients. The study found that Perceval, with its safe and reproducible features, allowed surgeons to employ a minimally invasive approach during AVR procedures. At follow-up at approximately 16 months, freedom from reoperation was 99% and patient survival was 91.3%. Perceval has been implanted in more than 20,000 patients in over 310 hospitals in 34 countries across the world.
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Companyâs next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.
LivaNova, PLC Announces New Data Reinforce the Clinical Value of the Perceval Sutureless Valve as Safe and Effective Bioprosthesis for Patients in Need of Aortic Valve Replacement